The idea of precision medicine – delivering the right drug treatment to the right patient at the right time and at the right dose – underpins current thinking in pharma R&D. by Zach Pitluk
The idea of precision medicine – delivering the right drug treatment to the right patient at the right time and at the right dose – underpins current thinking in pharma R&D. by Zach Pitluk
Single-cell technologies have positioned themselves at the forefront of biomedical research. These platforms allow researchers to bypass the uncertainties of bulk data and instead interrogate biological systems at a level of detail that was previously unreachable. But the value of these systems risks being impaired by bottlenecks in data analysis
New genetically-validated drug targets are found at accelerated speed using population scale biobank genotype-phenotype datasets after a foundational partnership is formed between Paradigm4 and Alnylam.
Advances in the single-cell genomic analysis of cells and tissues, including the required computational methods, have now put systematic, high-resolution and comprehensive reference maps of all human cells within our reach. Paradigm4’s Marilyn Matz, CEO and cofounder, and Dr Zachary Pitluk, VP of Life Sciences and Healthcare, report